Similar articles

• Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?

  Schuchter LM. Schuchter LM. J Clin Oncol. 2004 Jan 1;22(1):7-10. doi: 10.1200/JCO.2004.10.907. Epub 2003 Dec 9. J Clin Oncol. 2004. PMID: 14665612 No abstract available.
• Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.

  Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, Middleton MR, Thatcher N, Lorigan PC, Marsden JR, Burrows L, Gore M. Hancock BW, et al. J Clin Oncol. 2004 Jan 1;22(1):53-61. doi: 10.1200/JCO.2004.03.185. Epub 2003 Dec 9. J Clin Oncol. 2004. PMID: 14665609 Clinical Trial.
• Adjuvant therapy for malignant melanoma.

  Stoutenburg JP, Schrope B, Kaufman HL. Stoutenburg JP, et al. Expert Rev Anticancer Ther. 2004 Oct;4(5):823-35. doi: 10.1586/14737140.4.5.823. Expert Rev Anticancer Ther. 2004. PMID: 15485316 Review.
• Current management of melanoma: benefits of surgical staging and adjuvant therapy.

  McMasters KM, Swetter SM. McMasters KM, et al. J Surg Oncol. 2003 Mar;82(3):209-16. doi: 10.1002/jso.10216. J Surg Oncol. 2003. PMID: 12619066 Review.
• Adjuvant interferon therapy for melanoma.

  Hancock B, Wheatley K, Ives N, Gore M. Hancock B, et al. J Clin Oncol. 2005 Apr 1;23(10):2431; author reply 2431-2. doi: 10.1200/JCO.2005.99.260. J Clin Oncol. 2005. PMID: 15800339 No abstract available.